Strides Pharma Science is currently trading at Rs. 788.00, up by 16.90 points or 2.19% from its previous closing of Rs. 771.10 on the BSE.
The scrip opened at Rs. 761.00 and has touched a high and low of Rs. 792.90 and Rs. 761.00 respectively. So far 27885 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 898.00 on 08-Dec-2020 and a 52 week low of Rs. 271.00 on 20-Mar-2020.
Last one week high and low of the scrip stood at Rs. 812.40 and Rs. 761.00 respectively. The current market cap of the company is Rs. 7071.34 crore.
The promoters holding in the company stood at 29.69%, while Institutions and Non-Institutions held 42.24% and 28.07% respectively.
Strides Pharma Science’s (Strides) step-down wholly owned subsidiary, Strides Pharma Global Pte., Singapore, has received approval for Oxybutynin Chloride Tablets USP, 5 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Ditropan Tablets, 5 mg, of Janssen Pharmaceuticals, Inc.
According to IQVIA MAT October 2020 data, the US market for Oxybutynin Chloride Tablets USP, 5 mg is approximately $29 million. The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market. The company has 127 cumulative ANDA filings with USFDA of which 94 ANDAs have been approved and 33 are pending approval.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.00 |
Dr. Reddys Lab | 5942.65 |
Cipla | 1345.35 |
Zydus Lifesciences | 925.95 |
Lupin | 1547.05 |
View more.. |